English

Immune thrombocytopenia: what can the systems biology and systems physiology offer?

Introduction

Immune thrombocytopenia (ITP) is an acquired autoimmune disease, characterized by thrombocytopenia with platelet count lower than 100x109 plt/l without obvious causes for this
[
1
International consensus report on the investigation and management of primary immune thrombocytopenia

D. Provan, R. Stasi, A. Newland, V. Blanchette, P. Bolton-Maggs, J. Bussel, B. Chong, D. Cines, T. Gernsheimer, B. Godeau, J. Grainger, I. Greer, B. Hunt, P. Imbach, G. Lyons, R. McMillan, F. Rodeghiero, M. Sanz, M. Tarantino, S. Watson, J. Young, D. Kuter

Blood. 2010, 115, 168-186

]
. ITP manifests as hemorrhagic syndrome of various severity with such symptoms as ecchymosis, petechiae, spontaneous or post-traumatic bleedings, epistaxis, meno- and metrorrhagias, and rarely with gastrointestinal bleedings and hematuria
[
1
International consensus report on the investigation and management of primary immune thrombocytopenia

D. Provan, R. Stasi, A. Newland, V. Blanchette, P. Bolton-Maggs, J. Bussel, B. Chong, D. Cines, T. Gernsheimer, B. Godeau, J. Grainger, I. Greer, B. Hunt, P. Imbach, G. Lyons, R. McMillan, F. Rodeghiero, M. Sanz, M. Tarantino, S. Watson, J. Young, D. Kuter

Blood. 2010, 115, 168-186

]
. ITP is a common disorder with international incidence of 1.6 – 3.2 cases per 100.000 people a year
[
1,
International consensus report on the investigation and management of primary immune thrombocytopenia

D. Provan, R. Stasi, A. Newland, V. Blanchette, P. Bolton-Maggs, J. Bussel, B. Chong, D. Cines, T. Gernsheimer, B. Godeau, J. Grainger, I. Greer, B. Hunt, P. Imbach, G. Lyons, R. McMillan, F. Rodeghiero, M. Sanz, M. Tarantino, S. Watson, J. Young, D. Kuter

Blood. 2010, 115, 168-186

]
. ITP can manifest independently of age, though pediatric patients are more likely to be fully cured
[
4
Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database

M. Yong, W. Schoonen, L. Li, G. Kanas, J. Coalson, F. Mowat, J. Fryzek, J. Kaye

British Journal of Haematology. 2010, 149, 855-864

]
. About two-thirds of pediatric patients are fully recovered from ITP through the first year of disease even without any kind of therapy received
[
4
Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database

M. Yong, W. Schoonen, L. Li, G. Kanas, J. Coalson, F. Mowat, J. Fryzek, J. Kaye

British Journal of Haematology. 2010, 149, 855-864

]
.
A hallmark of ITP is anti-platelet antibodies in patient’s plasma
[
5
Platelet Autoantibodies in Immune Thrombocytopenic Purpura

D. Beardsley, M.D., Ph.D, M. Ertem, M.D

Transfusion Science. 1998, 19, 237-244

]
. They are specific for platelet glycoproteins
[
6
Specificity of autoantibodies in autoimmune thrombocytopenia

van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE.

Blood. 1982, 59, 23-26

]
. However, the causes of the emergence of antibodies can be either primary or secondary
. So, primary and secondary ITP are distinguished
[
1
International consensus report on the investigation and management of primary immune thrombocytopenia

D. Provan, R. Stasi, A. Newland, V. Blanchette, P. Bolton-Maggs, J. Bussel, B. Chong, D. Cines, T. Gernsheimer, B. Godeau, J. Grainger, I. Greer, B. Hunt, P. Imbach, G. Lyons, R. McMillan, F. Rodeghiero, M. Sanz, M. Tarantino, S. Watson, J. Young, D. Kuter

Blood. 2010, 115, 168-186

]
. Primary ITP is diagnosed when a separated decrease in platelet count without any predisposing etiology is observed
. The secondary ITP is diagnosed when some affecting platelet production or consumption cause was identified
[
]
. For example, some systemic diseases (systemic lupus erythematosus
, antiphospholipid syndrome
[
11
Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?

R. Tomasello, G. Giordano, F. Romano, F. Vaccarino, S. Siragusa, A. Lucchesi, M. Napolitano

Biomedicines. 2021, 9, 1170

]
), chronic infections (hepatitis C
, HIV infection
, H. pylori
[
14
Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori -associated chronic idiopathic thrombocytopenic purpura

T. Takahashi, T. Yujiri, K. Shinohara, Y. Inoue, Y. Sato, Y. Fujii, M. Okubo, Y. Zaitsu, K. Ariyoshi, Y. Nakamura, R. Nawata, Y. Oka, M. Shirai, Y. Tanizawa

British Journal of Haematology. 2004, 124, 91-96

]
), and lymphoproliferative diseases (CLL
) are known to affect platelet counts. Also, some therapy agents could affect platelets and thus cause ITP (for example, heparin-induced thrombocytopenia is considered to be one of ITP variants)
[
16
Drug-Induced Immune Thrombocytopenia

R. Aster, D. Bougie

New England Journal of Medicine. 2007, 357, 580-587

]
.
Generally, ITP progresses through three phases: acute, persistent and chronic. Newly diagnosed ITP (acute ITP) is the first period of the disease occurring in first three months from clinical manifestation of symptoms; the persistent ITP has a duration of 3-12 months from establishing the diagnosis, and the chronic form of ITP is diagnosed when clinical or/and laboratory markers are present for more than a year
[
1
International consensus report on the investigation and management of primary immune thrombocytopenia

D. Provan, R. Stasi, A. Newland, V. Blanchette, P. Bolton-Maggs, J. Bussel, B. Chong, D. Cines, T. Gernsheimer, B. Godeau, J. Grainger, I. Greer, B. Hunt, P. Imbach, G. Lyons, R. McMillan, F. Rodeghiero, M. Sanz, M. Tarantino, S. Watson, J. Young, D. Kuter

Blood. 2010, 115, 168-186

]
. About 75-80% of paediatric patients recover during the first 12 months from the diagnosis, about 15% develop the chronic form, and 0.1% of patients may decease because of severe hemorrhages
. The adults are more prone to develop the chronic form of ITP than children
[
17
Chronic Idiopathic Thrombocytopenic Purpura

J. George, M. El-Harake, G. Raskob

New England Journal of Medicine. 1994, 331, 1207-1211

]
.
There is no consistent treatment strategies for ITP, however, there are several recommended lines of therapy, based on the assumption that ITP was developed due to the presence of anti-platelet antibodies or platelet-targeted T-cells
[
1,
International consensus report on the investigation and management of primary immune thrombocytopenia

D. Provan, R. Stasi, A. Newland, V. Blanchette, P. Bolton-Maggs, J. Bussel, B. Chong, D. Cines, T. Gernsheimer, B. Godeau, J. Grainger, I. Greer, B. Hunt, P. Imbach, G. Lyons, R. McMillan, F. Rodeghiero, M. Sanz, M. Tarantino, S. Watson, J. Young, D. Kuter

Blood. 2010, 115, 168-186

18
Thrombopoietin receptor agonists for the treatment of severe persistent and chronic immune trombocytopenia in children: clinical data of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology

E. Suntsova, A. Maschan, O. Mironenko, D. Baydildina, I. Kalinina, M. Korsantya, N. Kotskaya, Z. Kuzminova, G. Ovsyannikova, U. Petrova, A. Pshonkin, M. Sadovskaya, T. Salimova, N. Trubina, D. Fedorova, G. Novichkova

Pediatric Hematology/Oncology and Immunopathology. None, 20, 12-25

]
. The first therapy line consists of injections of glucocorticosteroids (GCS) or intravenous immunoglobulins (IVIGs)
. GCS are widely used to reduce the overall immune response
[
20
Corticosteroids: The drugs to beat

P. Barnes

European Journal of Pharmacology. 2006, 533, 2-14

]
. The mechanism of IVIGs action is not yet clear, but it is believed that they competitively inhibit macrophage Fc-receptors and thus reduce antibody-mediated platelet clearance in spleen
. Additionally, IVIGs activate T-regulatory cells and inhibit differentiation and functioning of Th17s
. The efficacy of the first line therapy is about 70-80% with high probability of a relapse
[
]
. When GCS does not show significant efficacy, second line therapy could be used. There are different options for the second line. In some cases, an immune-suppressive therapy is used, i.e. mycophenolate mofetil
[
24
Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura

M. Hou, J. Peng, Y. Shi, C. Zhang, P. Qin, C. Zhao, X. Ji, X. Wang, M. Zhang

European Journal of Haematology. 2003, 70, 353-357

]
or cyclosporine
[
25
Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura

D. Choudhary, R. Naithani, M. Mahapatra, R. Kumar, P. Mishra, R. Saxena

Haematologica. 2008, 93, e61-e62

]
. Also, the suppressing B-cellular response anti-CD20 monoclonal antibody, rituximab, is efficient in ITP treatment
[
26
Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients

M. Khellaf, A. Charles-Nelson, O. Fain, L. Terriou, J. Viallard, S. Cheze, J. Graveleau, B. Slama, S. Audia, M. Ebbo, G. Le Guenno, M. Cliquennois, G. Salles, C. Bonmati, F. Teillet, L. Galicier, A. Hot, O. Lambotte, F. Lefrère, S. Sacko, D. Kengue, P. Bierling, F. Roudot-Thoraval, M. Michel, B. Godeau

Blood. 2014, 124, 3228-3236

]
. Additionally, platelet production in ITP could be increased by agonists of thrombopoietin receptors (TPO-RAs), those stimulate the thrombopoiesis
[
18,
Thrombopoietin receptor agonists for the treatment of severe persistent and chronic immune trombocytopenia in children: clinical data of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology

E. Suntsova, A. Maschan, O. Mironenko, D. Baydildina, I. Kalinina, M. Korsantya, N. Kotskaya, Z. Kuzminova, G. Ovsyannikova, U. Petrova, A. Pshonkin, M. Sadovskaya, T. Salimova, N. Trubina, D. Fedorova, G. Novichkova

Pediatric Hematology/Oncology and Immunopathology. None, 20, 12-25

27
Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

M. Lozano, M. Mingot-Castellano, M. Perera, I. Jarque, R. Campos-Alvarez, T. González-López, G. Carreño-Tarragona, N. Bermejo, M. Lopez-Fernandez, A. de Andrés, D. Valcarcel, L. Casado-Montero, M. Alvarez-Roman, M. Orts, S. Novelli, N. Revilla, J. González-Porras, E. Bolaños, M. Rodríguez-López, E. Orna-Montero, V. Vicente

Scientific Reports. 2019, 9, 16680

]
. As the last resort, platelet clearance could be significantly reduced by the resection of the spleen (splenectomy)
[
28,
Laparoscopic splenectomy for ITP

R. Friedman, M. Fallas, B. Carroll, J. Hiatt, E. Phillips

Surgical Endoscopy. 1996, 10, 991-995

]
. Unfortunately, even the splenectomy might fail to recover a patient’s platelet count
[
30
Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis

E. Bourgeois, M. Caulier, C. Delarozee, M. Brouillard, F. Bauters, P. Fenaux

British Journal of Haematology. 2003, 120, 1079-1088

]
, and it remains unclear whether the particular treatment approach would be effective.
It is noteworthy that primary ITP being a diagnosis of exclusion, it takes a long period of time to exclude all possible causes and that is why no straightforward diagnostic approach exists. Theoretically, any form of ITP could be diagnosed based on the presence of anti-platelet antibodies in patient’s blood
[
31
Anti‐platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications

D. Schmidt, K. Heitink‐Polle, L. Porcelijn, C. Schoot, G. Vidarsson, M. Bruin, M. Haas

Journal of Thrombosis and Haemostasis. 2020, 18, 1210-1220

]
. However, the availability of antiplatelet antibody assay is limited
[
32
Clinical Role of Antiplatelet Antibody Assays

R. McMillan

Seminars in Thrombosis and Hemostasis. 1995, 21, 37-45

]
. The transition of acute ITP to the chronic form is of high interest for clinicians as the probability of recovery from the chronic ITP is substantially lower than from the acute form
. However, there are still no definite predictors for such course of the disease, although several known risk factors include older age of manifestation, higher platelet count, and pre-manifestation vaccination
.
Systems biology approach might prove useful to develop diagnostic and predictive criteria for manifestation and progression of ITP and to evaluate the efficacy of the therapy options based on the phenotype of the patient. Here we discuss known mechanisms of ITP development and the in vitro, in vivo and in silico methods to study them.

Mechanisms of Immune thrombocytopenia

The molecular mechanisms of ITP development are poorly understood as there is no determined reason for the autoimmunity to unroll. Nevertheless, 60% of paediatric patients had a history of pre-manifestation viral infection
, or pre-manifestation vaccination against influenza
[
36
ITP following vaccination

P. David, Y. Shoenfeld

International Journal of Infectious Diseases. 2020, 99, 243-244

]
, measles virus, rubella virus, and mumps
[
37
MMR vaccine and idiopathic thrombocytopaenic purpura

C. Black, J. Kaye, H. Jick

British Journal of Clinical Pharmacology. 2003, 55, 107-111

]
. Though the starting point of acute ITP is uncertain, the mechanisms of autoimmune response were widely studied in chronic patients. Here, the dysregulations in both the humoral (B-cell) and the cellular (T-cell) parts of the immune system have been reported (Figure 1).
Schematic of immune thrombocytopenia mechanisms. The thrombocytopenia in patients could be caused by both T-cells cytotoxicity (CTLs are more active because T-regulatory cells and T-helpers provide dysregulated stimuli) and B-cells antibody production (plasma cells are producing antiplatelet antibodies of IgG and IgM classes; B-regulatory cells provide more activating signals to B-cells to produce antibodies). CTLs specifically attack platelets and induce their apoptosis. Antibodies from plasma cells opsonize platelets. Consecutively, opsonized platelets are eliminated through the spleen. CTLs – cytotoxic T-lymphocytes; Treg – T-regulatory cell; Th – T-helper; Breg – B-regulatory cell; BAFF – B-cell activating factor.
Figure 1. Schematic of immune thrombocytopenia mechanisms. The thrombocytopenia in patients could be caused by both T-cells cytotoxicity (CTLs are more active because T-regulatory cells and T-helpers provide dysregulated stimuli) and B-cells antibody production (plasma cells are producing antiplatelet antibodies of IgG and IgM classes; B-regulatory cells provide more activating signals to B-cells to produce antibodies). CTLs specifically attack platelets and induce their apoptosis. Antibodies from plasma cells opsonize platelets. Consecutively, opsonized platelets are eliminated through the spleen. CTLs – cytotoxic T-lymphocytes; Treg – T-regulatory cell; Th – T-helper; Breg – B-regulatory cell; BAFF – B-cell activating factor.

B-cells involvement in ITP

Most ITP patients have high plasma levels of antibodies against platelet and megakaryocyte cell membrane glycoproteins. The most commonly met ones are anti-GPIbα and anti-GPIIb-IIIa
[
31
Anti‐platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications

D. Schmidt, K. Heitink‐Polle, L. Porcelijn, C. Schoot, G. Vidarsson, M. Bruin, M. Haas

Journal of Thrombosis and Haemostasis. 2020, 18, 1210-1220

]
. Antibodies of IgG and IgM classes are more frequently found than the IgA class
[
31,
Anti‐platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications

D. Schmidt, K. Heitink‐Polle, L. Porcelijn, C. Schoot, G. Vidarsson, M. Bruin, M. Haas

Journal of Thrombosis and Haemostasis. 2020, 18, 1210-1220

]
. It is well established that in ITP, the opsonization of platelets with the antibodies causes their elimination through the spleen in an Fc-dependent manner
[
40
FcγRI and FcγRIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb/IIIa autoantibody-opsonized platelets in immune thrombocytopenia

P. Norris, G. Segel, W. Burack, U. Sachs, S. Lissenberg-Thunnissen, G. Vidarsson, B. Bayat, C. Cserti-Gazdewich, J. Callum, Y. Lin, D. Branch, R. Kapur, J. Semple, A. Lazarus

Haematologica. 2020, 106, 250-254

]
.
It is well-known that B-cells are responsible for the production of antibodies
[
]
. There are 100-900 naïve B cells in 1 µl of human blood and much more in lymphatic vessels and nodes
[
42
Reference values for B cell subpopulations from infancy to adulthood

H. Morbach, E. Eichhorn, J. Liese, H. Girschick

Clinical and Experimental Immunology. 2010, 162, 271-279

]
. All of them have specific B-cell receptors (BCRs) specific for some antigens. When a BCR meets its specific ligands and B cell receives additional signals from helper T cells, toll-like receptor ligands and other factors the differentiation of the naive B cells into PCs may start the differentiation of the naïve B-cell into a plasma cell
. The plasma cells produce specific antibodies against the recognized antigen
[
44
Regulation of plasma-cell development

M. Shapiro-Shelef, K. Calame

Nature Reviews Immunology. 2005, 5, 230-242

]
. Normally, naïve B-cells with BCRs reactive to autologous proteins are driven to be anergic to avoid the autoimmune reaction
[
45
Receptor editing: an approach by autoreactive B cells to escape tolerance.

D. Gay, T. Saunders, S. Camper, M. Weigert

Journal of Experimental Medicine. 1993, 177, 999-1008

]
, but in ITP the mechanism of “turning off” the autoreactive B-cells is somehow disrupted. Fang et al.
have shown that patients with ITP have higher B-cells (CD19+) counts than healthy donors, as well as less regulatory B-cells, responsible for the suppression of an autoimmune response
[
]
, and more memory B-cells, those are specific for previously met antigens
. Therefore, it could be stated, that ITP patients with antiplatelet antibodies have disrupted regulation of B-cellular immunity. Taking into account that the B-cells activating factor (BAFF) and its mRNA are also elevated in ITP patients
[
48
The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia

X. Zhu, Y. Shi, J. Peng, C. Guo, N. Shan, P. Qin, X. Ji, M. Hou

Blood. 2009, 114, 5362-5367

]
, the autoreactive B-cells survive better.

T-cellular mechanism of ITP

Some ITP patients do not have anti-platelet antibodies
[
31
Anti‐platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications

D. Schmidt, K. Heitink‐Polle, L. Porcelijn, C. Schoot, G. Vidarsson, M. Bruin, M. Haas

Journal of Thrombosis and Haemostasis. 2020, 18, 1210-1220

]
. Zhai et al.
[
49
Flow cytometric immunobead assay for quantitative detection of platelet autoantibodies in immune thrombocytopenia patients

J. Zhai, M. Ding, T. Yang, B. Zuo, Z. Weng, Y. Zhao, J. He, Q. Wu, C. Ruan, Y. He

Journal of Translational Medicine. 2017, 15, 214

]
have shown that the concentrations of the anti-platelet antibodies in the blood of patients with chronic ITP are significantly lower than for the ones with newly diagnosed or persistent ITP. Therefore, it can be expected that not only humoral immunity contributes to the ITP pathogenesis. Indeed, T-cellular immunity dysregulation ITP was earlier described
. T-cellular mechanism of ITP is assumed to constitute in T-killers’ action against platelet specific antigens, and the T-helpers and T-regulatory cells are also actively involved in the ITP pathogenesis.
T-killers (cytotoxic T-cells, CTLs) are the CD8+ T-cells that are responsible for the cytotoxic immune response
[
52
Cytotoxic T lymphocytes: all roads lead to death

M. Barry, R. Bleackley

Nature Reviews Immunology. 2002, 2, 401-409

]
. All T-cells recognize specific antigens through their receptors, TCRs (T-cell receptors) [53]. A high-affinity binding of a specific TCR to MHC-peptide complex induces IL-2-dependent proliferation of T-cell with this TCR structure [54]. The mature CTL induces apoptosis in the target cell by means of its secreted perforins and granzymes [52]. Perforins are the proteins that bind to the target cell’s membrane and induce a pore formation to let the serine proteases granzymes (especially granzyme B) enter the cell and thus induce apoptosis [55] through the intrinsic pathway [56].
In order to support the hypothesis of In order to support the hypothesis of CTLs involvement in ITP, Zhang et al. analyzed gene expression in CD8+ cells of patients with chronic ITP [57]. have shown that c Patients had elevated expression of perforins, granzyme B, TNFa, FasL and TRAIL protein – markers of the CTL activity and ongoing apoptosis. In line with this, Zhu et al. have demonstrated an increased level of IL-21, which is produced upon CTL activation [58]. In another study platelets from patients with chronic ITP demonstrated enhanced markers of apoptosis such as increased mitochondrial collapse, phosphatidylserine exposure, and amounts of pro-apoptotic proteins [59,60]. Altogether, these data points at the active role of CTLs in ITP pathogenesis.
T-helpers (Th) are CD4+ cells that modulate both the B-cellular and the T-cellular responses [61]. Different populations of T-helpers have diverse effects due to their secretory profile: Th1 produces IL-1, Th17 secretes IL-17, etc. [62]. ]. Naïve T-helpers, as well as CTLs, are activated upon exposure to the antigen [63]. Activity of the mature T- helpers is diverse: while Th1 promotes the proliferation of cytotoxic lymphocytes, Th2 stimulates the humoral immunity to produce more immunoglobulins [64]. Thus, both Th1 and Th2 can contribute to autoimmune diseases, such as ITP. Th17 [65] and Th22 [66–68] also can be involved in the ITP pathogenesis. Imbalance between Th1 and Th2 is considered to be a marker of immunity dysregulation [69] ]. In line with this, ITP patients have increased levels of Th1 [58]. Increased levels of Th17 and Th22 also were observed in ITP patients together with increased plasma concentration of IL-1, IL-17, and IL-22 [70,71].
Regulatory T-cells (Tregs) are a subpopulation of T-helpers those are characterized by high expression of Foxp3 gene [72,73]. Tregs regulate proliferation of the B- and T-cells, reducing their activity in case of overreactive immune response [73]. Tregs counts, as well as Foxp3 expression are decreased in ITP patients [74]. And the balance between Th1, Th17, and Treg is disrupted in ITP ], probably due to the overproduction of the IL- 17A [71] and IL-21 [58] , which are negative regulators of Treg differentiation [73].

Basic research approaches to study Immune thrombocytopenia

The approaches to the determination of fundamental ITP mechanisms are diverse with both in vivo, ex vivo, in vitro and in silico assays reported. Here we briefly describe the existing methods of ITP mechanisms evaluation with specific accent on animal models on the one hand and systems biology studies on the other.

In vivo approaches to study ITP pathogenesis

Rodent-based animal studies, especially murine ones, have become the “golden standard” for the studies of the disease pathology in mammals. Murine models of ITP can be roughly divided into acute ITP and chronic ITP models. Acute models are based on the direct injection of the antiplatelet antibodies into animals, while chronic models are mostly based on transgenic mice (Figure 2). Thus, both B- and T-cell dependent mechanisms of ITP development can be mimicked using mice.
Existing murine models of primary immune thrombocytopenia. There are several approaches to develop ITP in a mouse. The first one is based on antiplatelet antibodies injections into WT mouse. The second model is based on perfusion of CD25 depleted regulatory T-cells into nude mice, causing a dysregulation in the immune system. On the other hand, an autoimmune reaction can be caused upon transfusion of normal platelets into a CD61-knockout mouse. CD25 depleted Tregs – CD25 depleted regulatory T-cells; anti-CD41 – antibodies against platelet CD41; MwReg30 – rat monoclonal antibody against mice CD41.
Figure 2. Existing murine models of primary immune thrombocytopenia. There are several approaches to develop ITP in a mouse. The first one is based on antiplatelet antibodies injections into WT mouse. The second model is based on perfusion of CD25 depleted regulatory T-cells into nude mice, causing a dysregulation in the immune system. On the other hand, an autoimmune reaction can be caused upon transfusion of normal platelets into a CD61-knockout mouse. CD25 depleted Tregs – CD25 depleted regulatory T-cells; anti-CD41 – antibodies against platelet CD41; MwReg30 – rat monoclonal antibody against mice CD41.
Generally, acute ITP is modeled using antiplatelet antibodies-based approaches targeted approaches, which are the most commonly used techniques to study ITP in vivo. The mice are injected with rabbit- produced or rat-produced anti-CD61 or anti-CD41 antibodies once or repeatedly, with MwReg30 anti-CD41 antibody being the most widely used [75]. As no active autoimmune reaction is ongoing in the organism, such models are called “passive” and is among the most trivial model of murine ITP. Antibody injection causes opsonization of platelets and their subsequent elimination by macrophages in spleen or liver [76]. It is noteworthy that anti-CD61 antibodies cause more severe thrombocytopenia than the anti-CD41 antibodies [76], probably due to the fact that anti-CD61 antibodies are responsible for the Fc- dependent elimination of platelets through the spleen [77].
The “passive” ITP models are useful for the studies of therapy impact on the pathology development [78]. This approach allowed to identify the mechanism of action of IVIG in ITP: it appeared that IVIG inhibited the Fc-dependent elimination of platelets through the spleen [77]. However, “passive” models of ITP in mice with single antibody injections are not suitable to study the mechanisms of the transformation of acute ITP to its chronic form as no autoimmune process is ongoing in antibody-injected mice. However, development of the specific regimes of repeated injections of antiplatelet antibodies with escalating dosage regimen can mimic chronic ITP. For this injections of anti-CD41 antibodies (MwReg30) daily with escalating the dose from 7 ug/ml at Day 0 to 21 ug/ml at Day 5 into mice have been done [75]. In these circumstances platelets are constantly consumed what resembles processes ongoing in chronic ITP in human patients. Indeed, such approach is still rather incorrect in contrast to more sophisticated models of chronic ITP in mice [75].
Development of chronic ITP in mice can be reached with repeated injections of antiplatelet antibodies with escalating dosage regimen. The other way to form the chronic ITP is to sensitize the mice to the platelet CD61. In the first model the mice receive the anti-CD41 antibodies (MwReg30) daily with escalating the dose from 7 ug/ml at Day 0 to 21 ug/ml at Day 5 [75]. In this model the platelets are destroyed all of the time, so it seems to be closer to the human disease. Nevertheless, the studies of this model are limited to 1 week for performing the experiments [75].
The other approach to the development of the chronic ITP is based on some sensitization of the animal to CD61. For this, a CD61 knockout (CD61 KO) mice are perfused with platelets from WT mice [79,80]. This causes activation of immunity what results in the both clinical and laboratory symptoms of ITP: profound thrombocytopenia, hemorrhagic syndrome up to fatal bleedings [79]. This type of in vivo model is more likely to imitate the “natural” course of ITP from the first manifestation until the clinical outcome. However, even though such model is closely resembling ITP in human patients, sensibilized to CD61 mice do not recover from ITP, while patients can overcome the disease [33].
T-cellular models are less common than B-cellular due to their complexity. The most elegant one is based on the CD25 depleted mice. The CD4+ cells from well characterized CD25 depleted mice [81] are transfused into nude mice. 36% of recipients develop severe isolated thrombocytopenia on the 3rd and consecutive weeks [82,83]. That model is a reflection of a classical ITP manifestation with spontaneous hemorrhagic syndrome and isolated thrombocytopenia. Unlike the CD61-sensibilization based model, Treg-based one does not cause fatal consequences. Despite all of the advances in the in vivo studies, murine immunity significantly differs from human, what severely limits applicability of rodent models [84].

In silico approaches to studies ITP

In silico approach is a convenient tool for studying the biological and physiological systems [85,86]. Computational models of intracellular signaling or intercellular interactions can predict the response of the system to different stimuli. Patient-based computational models could predict treatment efficacy and help the clinician to choose the dosage regimen to improve the quality of life of the patient. Thus, computational modeling could be of use for ITP research. However, there are only two computational models related to ITP.
The first model is designed by Wire et al. [87] for evaluating the dosage regimen for eltrombopag in immune thrombocytopenia patients. This model describes pharmacokinetics (PK) and pharmacodynamics (PD) of the drug and thus allows correction of the therapy dosage in personalized mode. Age and race are among the parameters that define the optimal dosage of eltrombopag in that model. Interestingly, it appeared that the body weight is insignificant to the PK/PD of this TPO-RA. It remains unpredictable if the platelet count would increase effectively, so it is still necessary to monitor the platelet count. Nevertheless, the patient-based regimen of eltrombopag administration is more convenient to be selected and adapted, with this model. This model might be implemented in studying the PK/PD of other types of pharmacology treatment options for immune thrombocytopenia as well.
The second model was published by our group to describe two platelet phenotypes in immune thrombocytopenia [88] . Platelets of ITP patients have been shown to bind to fibrinogen in different ways. Platelets of one group of patients bind fibrinogen less fibrinogen than healthy donors (comparable to Glanzmann’s thrombasthenia patients). The platelets of the other of ITP patients have increased fibrinogen binding. Furthermore, the platelets of ITP patients are pre-activated in the quiescent state which is detected with the increased cytosolic calcium. The cause of the formation of different subtypes of platelets remains unclear. The authors hypothesize that antiplatelet antibodies of different specificity might be the reason. Considering that anti-GPIb antibodies are able to activate platelets, the model can be extended for predicting the platelet phenotype of activation based on the results of the antibody testing in a concrete patient. So that more specific therapeutic approach might be considered.
Finally, models of different phenomena can also be applicable for the studies of ITP. Stepanyan et al. [89] have developed a stochastic computational model of platelets’ life cycle which takes into the account the consumption of platelets due to COVID-19 thrombosis. Briefly, the platelets are produced in the megakaryocytes from the bone marrow with a TPO level dependent manner. The newly produced platelets circulate in the blood for 7-10 days if no event occurs. Then the platelets are either eliminated through the liver what results in TPO level rise, or can be consumed due to ongoing thrombosis in lung microvasculature. This model can be implemented into studying the ITP mechanisms by adding any cells or events that can affect the platelet life cycle. It is of additional interest, how the addition of cytotoxic T-lymphocytes would affect platelet lifespan in such model.

Conclusion

ITP is a complex disease with diverse and poorly characterized initiation mechanisms and complex diagnostics. Generally, the treatment of ITP is aimed at suppressing the immune system function, increasing platelet production or decreasing platelet consumption by splenectomy, but there is no treatment aimed at the origin of the decease. Besides, the ITP therapy itself can induce transition from acute to chronic phase of ITP.
Basic science ITP research has flourished in the last couple of decades with a lot of new approached being developed. The murine models are the most common option to study the effects of various novel therapies, while computational modeling might be productive in describing the patient’s phenotype based on the clinical and laboratory parameters. So, the computational modeling might be a useful tool to construct a tool for personalized predictions of the disease progression and therapy efficacy.

Acknowledgments

The study was supported by a grant from the endowment foundation "Science for Children". Images were created using BioRender (https://biorender.com/)

Author Contributions

O.I.A. planned the study and wrote the paper; A.A.M. analyzed the data and edited the paper; M.A.P. supervised the study, analyzed the data and edited the paper. All authors have read and agreed to the published version of the manuscript. The authors declare no conflict of interests.

References of this article:

  1. International consensus report on the investigation and management of primary immune thrombocytopenia

    D. Provan, R. Stasi, A. Newland, V. Blanchette, P. Bolton-Maggs, J. Bussel, B. Chong, D. Cines, T. Gernsheimer, B. Godeau, J. Grainger, I. Greer, B. Hunt, P. Imbach, G. Lyons, R. McMillan, F. Rodeghiero, M. Sanz, M. Tarantino, S. Watson, J. Young, D. Kuter

    Blood. 2010, 115, 168-186

  2. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia

    C. Neunert, W. Lim, M. Crowther, A. Cohen, L. Solberg, M. Crowther

    Blood. 2011, 117, 4190-4207

  3. Chronic Immune Thrombocytopenia in Adults: Epidemiology and Clinical Presentation

    P. Fogarty

    Hematology/Oncology Clinics of North America. 2009, 23, 1213-1221

  4. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database

    M. Yong, W. Schoonen, L. Li, G. Kanas, J. Coalson, F. Mowat, J. Fryzek, J. Kaye

    British Journal of Haematology. 2010, 149, 855-864

  5. Platelet Autoantibodies in Immune Thrombocytopenic Purpura

    D. Beardsley, M.D., Ph.D, M. Ertem, M.D

    Transfusion Science. 1998, 19, 237-244

  6. Specificity of autoantibodies in autoimmune thrombocytopenia

    van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE.

    Blood. 1982, 59, 23-26

  7. SIMILARITIES BETWEEN KNOWN ANTIPLATELET ANTIBODIES AND THE FACTOR RESPONSIBLE FOR THROMBOCYTOPENIA IN IDIOPATHIC PURPURA. PHYSIOLOGIC, SEROLOGIC AND ISOTOPIC STUDIES

    N. Shulman, V. Marder, R. Weinrach

    Annals of the New York Academy of Sciences. 2006, 124, 499-542

  8. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry

    D. Arnold, I. Nazy, R. Clare, A. Jaffer, B. Aubie, N. Li, J. Kelton

    Blood Advances. 2017, 1, 2414-2420

  9. Pathobiology of Secondary Immune Thrombocytopenia

    D. Cines, H. Liebman, R. Stasi

    Seminars in Hematology. 2009, 46, S2-S14

  10. Thrombocytopenia in patients with systemic lupus erythematosus: significant in the clinical implication and prognosis

    H. Zhao, S. Li, R. Yang

    Platelets. 2010, 21, 380-385

  11. Immune Thrombocytopenia in Antiphospholipid Syndrome: Is It Primary or Secondary?

    R. Tomasello, G. Giordano, F. Romano, F. Vaccarino, S. Siragusa, A. Lucchesi, M. Napolitano

    Biomedicines. 2021, 9, 1170

  12. Role of molecular mimicry of hepatitis C virus protein with platelet GPIIIa in hepatitis C–related immunologic thrombocytopenia

    W. Zhang, M. Nardi, W. Borkowsky, Z. Li, S. Karpatkin

    Blood. 2009, 113, 4086-4093

  13. Role of molecular mimicry to HIV-1 peptides in HIV-1–related immunologic thrombocytopenia

    Z. Li, M. Nardi, S. Karpatkin

    Blood. 2005, 106, 572-576

  14. Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori -associated chronic idiopathic thrombocytopenic purpura

    T. Takahashi, T. Yujiri, K. Shinohara, Y. Inoue, Y. Sato, Y. Fujii, M. Okubo, Y. Zaitsu, K. Ariyoshi, Y. Nakamura, R. Nawata, Y. Oka, M. Shirai, Y. Tanizawa

    British Journal of Haematology. 2004, 124, 91-96

  15. Immune thrombocytopenia in lymphoproliferative diseases

    B. Kaden, W. Rosse, T. Hauch

    Blood. 1979, 53, 545-551

  16. Drug-Induced Immune Thrombocytopenia

    R. Aster, D. Bougie

    New England Journal of Medicine. 2007, 357, 580-587

  17. Chronic Idiopathic Thrombocytopenic Purpura

    J. George, M. El-Harake, G. Raskob

    New England Journal of Medicine. 1994, 331, 1207-1211

  18. Thrombopoietin receptor agonists for the treatment of severe persistent and chronic immune trombocytopenia in children: clinical data of Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology, Immunology

    E. Suntsova, A. Maschan, O. Mironenko, D. Baydildina, I. Kalinina, M. Korsantya, N. Kotskaya, Z. Kuzminova, G. Ovsyannikova, U. Petrova, A. Pshonkin, M. Sadovskaya, T. Salimova, N. Trubina, D. Fedorova, G. Novichkova

    Pediatric Hematology/Oncology and Immunopathology. , 20, 12-25

  19. First-Line Therapy for Immune Thrombocytopenia

    S. Mithoowani, D. Arnold

    Hämostaseologie. 2019, 39, 259-265

  20. Corticosteroids: The drugs to beat

    P. Barnes

    European Journal of Pharmacology. 2006, 533, 2-14

  21. Sialylation-independent mechanism involved in the amelioration of murine immune thrombocytopenia using intravenous gammaglobulin

    D. Leontyev, Y. Katsman, X. Ma, S. Miescher, F. Käsermann, D. Branch

    Transfusion. 2012, 52, 1799-1805

  22. Intravenous immunoglobulin therapy enhances suppressive regulatory T cells and decreases innate lymphoid cells in children with immune thrombocytopenia

    S. Wang, K. Yang, C. Lin, A. Huang, C. Hsiao, M. Lin, Y. Tsai

    Pediatric Blood & Cancer. 2020, 67,

  23. High-dose dexamethasone as a first- and second-line treatment of idiopathic thrombocytopenic purpura in adults

    F. Borst, J. Keuning, H. van Hulsteijn, H. Sinnige, G. Vreugdenhil

    Annals of Hematology. 2004, 83, 764-768

  24. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura

    M. Hou, J. Peng, Y. Shi, C. Zhang, P. Qin, C. Zhao, X. Ji, X. Wang, M. Zhang

    European Journal of Haematology. 2003, 70, 353-357

  25. Efficacy of cyclosporine as a single agent therapy in chronic idiopathic thrombocytopenic purpura

    D. Choudhary, R. Naithani, M. Mahapatra, R. Kumar, P. Mishra, R. Saxena

    Haematologica. 2008, 93, e61-e62

  26. Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients

    M. Khellaf, A. Charles-Nelson, O. Fain, L. Terriou, J. Viallard, S. Cheze, J. Graveleau, B. Slama, S. Audia, M. Ebbo, G. Le Guenno, M. Cliquennois, G. Salles, C. Bonmati, F. Teillet, L. Galicier, A. Hot, O. Lambotte, F. Lefrère, S. Sacko, D. Kengue, P. Bierling, F. Roudot-Thoraval, M. Michel, B. Godeau

    Blood. 2014, 124, 3228-3236

  27. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia

    M. Lozano, M. Mingot-Castellano, M. Perera, I. Jarque, R. Campos-Alvarez, T. González-López, G. Carreño-Tarragona, N. Bermejo, M. Lopez-Fernandez, A. de Andrés, D. Valcarcel, L. Casado-Montero, M. Alvarez-Roman, M. Orts, S. Novelli, N. Revilla, J. González-Porras, E. Bolaños, M. Rodríguez-López, E. Orna-Montero, V. Vicente

    Scientific Reports. 2019, 9, 16680

  28. Laparoscopic splenectomy for ITP

    R. Friedman, M. Fallas, B. Carroll, J. Hiatt, E. Phillips

    Surgical Endoscopy. 1996, 10, 991-995

  29. Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?

    F. Rodeghiero, M. Ruggeri

    British Journal of Haematology. 2012, 158, 16-29

  30. Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis

    E. Bourgeois, M. Caulier, C. Delarozee, M. Brouillard, F. Bauters, P. Fenaux

    British Journal of Haematology. 2003, 120, 1079-1088

  31. Anti‐platelet antibodies in childhood immune thrombocytopenia: Prevalence and prognostic implications

    D. Schmidt, K. Heitink‐Polle, L. Porcelijn, C. Schoot, G. Vidarsson, M. Bruin, M. Haas

    Journal of Thrombosis and Haemostasis. 2020, 18, 1210-1220

  32. Clinical Role of Antiplatelet Antibody Assays

    R. McMillan

    Seminars in Thrombosis and Hemostasis. 1995, 21, 37-45

  33. Mechanisms of platelet recovery in ITP associated with therapy

    S. Pang, A. Lazarus

    Annals of Hematology. 2010, 89, 31-35

  34. Clinical and laboratory predictors of chronic immune thrombocytopenia in children: a systematic review and meta-analysis

    K. Heitink-Pollé, J. Nijsten, C. Boonacker, M. de Haas, M. Bruin

    Blood. 2014, 124, 3295-3307

  35. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the intercontinental childhood ITP study group

    T. Kühne, G. Buchanan, S. Zimmerman, L. Michaels, R. Kohan, W. Berchtold, P. Imbach

    The Journal of Pediatrics. 2003, 143, 605-608

  36. ITP following vaccination

    P. David, Y. Shoenfeld

    International Journal of Infectious Diseases. 2020, 99, 243-244

  37. MMR vaccine and idiopathic thrombocytopaenic purpura

    C. Black, J. Kaye, H. Jick

    British Journal of Clinical Pharmacology. 2003, 55, 107-111

  38. Spectrum of Ig Classes, Specificities, and Titers of Serum Antiglycoproteins in Chronic Idiopathic Thrombocytopenic Purpura

    He R, Reid DM, Jones C, Shulman NR

    Blood. 1994, 83 (4), 1024-32

  39. Platelet autoantibodies (IgG, IgM, IgA) against glycoproteins IIb/IIIa and Ib/IX in patients with thrombocytopenia

    V. Kiefel, E. Freitag, H. Kroll, S. Santoso, C. Mueller-Eckhardt

    Annals of Hematology. 1996, 72, 280-285

  40. FcγRI and FcγRIII on splenic macrophages mediate phagocytosis of anti-glycoprotein IIb/IIIa autoantibody-opsonized platelets in immune thrombocytopenia

    P. Norris, G. Segel, W. Burack, U. Sachs, S. Lissenberg-Thunnissen, G. Vidarsson, B. Bayat, C. Cserti-Gazdewich, J. Callum, Y. Lin, D. Branch, R. Kapur, J. Semple, A. Lazarus

    Haematologica. 2020, 106, 250-254

  41. Immune Regulatory Function of B Cells

    C. Mauri, A. Bosma

    Annual Review of Immunology. 2012, 30, 221-241

  42. Reference values for B cell subpopulations from infancy to adulthood

    H. Morbach, E. Eichhorn, J. Liese, H. Girschick

    Clinical and Experimental Immunology. 2010, 162, 271-279

  43. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling

    S. Herzog, M. Reth, H. Jumaa

    Nature Reviews Immunology. 2009, 9, 195-205

  44. Regulation of plasma-cell development

    M. Shapiro-Shelef, K. Calame

    Nature Reviews Immunology. 2005, 5, 230-242

  45. Receptor editing: an approach by autoreactive B cells to escape tolerance.

    D. Gay, T. Saunders, S. Camper, M. Weigert

    Journal of Experimental Medicine. 1993, 177, 999-1008

  46. The imbalance between regulatory memory B cells reveals possible pathogenesis involvement in pediatric immune thrombocytopenia

    J. Fang, L. Lin, D. Lin, R. Zhang, X. Liu, D. Wang, C. Duan, X. Lin

    Hematology. 2019, 24, 473-479

  47. Memory B-cell persistence is independent of persisting immunizing antigen

    M. Maruyama, K. Lam, K. Rajewsky

    Nature. 2000, 407, 636-642

  48. The effects of BAFF and BAFF-R-Fc fusion protein in immune thrombocytopenia

    X. Zhu, Y. Shi, J. Peng, C. Guo, N. Shan, P. Qin, X. Ji, M. Hou

    Blood. 2009, 114, 5362-5367

  49. Flow cytometric immunobead assay for quantitative detection of platelet autoantibodies in immune thrombocytopenia patients

    J. Zhai, M. Ding, T. Yang, B. Zuo, Z. Weng, Y. Zhao, J. He, Q. Wu, C. Ruan, Y. He

    Journal of Translational Medicine. 2017, 15, 214

  50. Cellular immune dysregulation in the pathogenesis of immune thrombocytopenia

    R. Wen, Y. Wang, Y. Hong, Z. Yang

    Blood Coagulation & Fibrinolysis. 2020, 31, 113-120

  51. Immune Thrombocytopenia: A Complex Autoimmune Disease

    Lee E-J, Bussel JB

    The Autoimmune Diseases, Elsevier. 2020, , 911-21

  52. Cytotoxic T lymphocytes: all roads lead to death

    M. Barry, R. Bleackley

    Nature Reviews Immunology. 2002, 2, 401-409

  53. Signal transduction by the TCR for antigen

    L. Kane, J. Lin, A. Weiss

    Current Opinion in Immunology. 2000, 12, 242-249

  54. Metabolism in T cell activation and differentiation

    E. Pearce

    Current Opinion in Immunology. 2010, 22, 314-320

  55. Perforin and granzymes: function, dysfunction and human pathology

    I. Voskoboinik, J. Whisstock, J. Trapani

    Nature Reviews Immunology. 2015, 15, 388-400

  56. Initiation of Apoptosis by Granzyme B Requires Direct Cleavage of Bid, but Not Direct Granzyme B–Mediated Caspase Activation

    V. Sutton, J. Davis, M. Cancilla, R. Johnstone, A. Ruefli, K. Sedelies, K. Browne, J. Trapani

    Journal of Experimental Medicine. 2000, 192, 1403-1414

  57. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura

    F. Zhang, X. Chu, L. Wang, Y. Zhu, L. Li, D. Ma, J. Peng, M. Hou

    European Journal of Haematology. 2006, 76, 427-431

  58. Elevated Interleukin-21 Correlated to Th17 and Th1 Cells in Patients with Immune Thrombocytopenia

    X. Zhu, D. Ma, J. Zhang, J. Peng, X. Qu, C. Ji, M. Hou

    Journal of Clinical Immunology. 2010, 30, 253-259

  59. Investigation of platelet apoptosis in adult patients with chronic immune thrombocytopenia

    G. Deng, S. Yu, Q. Li, Y. He, W. Liang, L. Yu, D. Xu, T. Sun, R. Zhang, Q. Li

    Hematology. 2017, 22, 155-161

  60. Pediatric immune thrombocytopenia: apoptotic markers may help in predicting the disease course

    S. Levy-Mendelovich, S. Aviner, N. Sharon, H. Miskin, J. Yacobovich, G. Kenet, H. Hauschner, N. Rosenberg

    Pediatric Research. 2021, 90, 93-98

  61. Regulation of human helper T cell subset differentiation by cytokines

    N. Schmitt, H. Ueno

    Current Opinion in Immunology. 2015, 34, 130-136

  62. CD4+T Cells: Differentiation and Functions

    R. Luckheeram, R. Zhou, A. Verma, B. Xia

    Clinical and Developmental Immunology. 2012, 2012, 1-12

  63. A Three-cell Model for Activation of Naïve T Helper Cells

    A. Corthay

    Scandinavian Journal of Immunology. 2006, 64, 93-96

  64. TH1 and TH2 cells: a historical perspective

    F. Liew

    Nature Reviews Immunology. 2002, 2, 55-60

  65. IL-17 and Th17 Cells

    T. Korn, E. Bettelli, M. Oukka, V. Kuchroo

    Annual Review of Immunology. 2009, 27, 485-517

  66. IL-22 Produced by T helper Cell 22 as a New player in the Pathogenesis of Immune Thrombocytopenia

    G. Azizi, R. Yazdani, K. Hamid, A. Razavi, A. Mirshafiey

    Endocrine, Metabolic & Immune Disorders-Drug Targets. 2015, 15, 242-250

  67. Importance of Th22 Cell Disequilibrium in Immune Thrombocytopenic Purpura

    F. Zhan, J. Li, M. Fang, J. Ding, Q. Wang

    Medical Science Monitor. , 24, 8767-8772

  68. Effects of High-Dose Dexamethasone on Regulating Interleukin-22 Production and Correcting Th1 and Th22 Polarization in Immune Thrombocytopenia

    J. Cao, C. Chen, L. Li, L. Zeng, Z. Li, Z. Yan, W. Chen, H. Cheng, W. Sang, K. Xu

    Journal of Clinical Immunology. 2012, 32, 523-529

  69. The Th1/Th2 balance in autoimmunity

    B. Charlton, K. Lafferty

    Current Opinion in Immunology. 1995, 7, 793-798

  70. Elevated profiles of Th22 cells and correlations with Th17 cells in patients with immune thrombocytopenia

    Y. Hu, H. Li, L. Zhang, B. Shan, X. Xu, H. Li, X. Liu, S. Xu, S. Yu, D. Ma, J. Peng, M. Hou

    Human Immunology. 2012, 73, 629-635

  71. The levels of IL-17A and of the cytokines involved in Th17 cell commitment are increased in patients with chronic immune thrombocytopenia

    A. Rocha, C. Souza, G. Rocha, F. de Melo, N. Clementino, M. Marino, A. Bozzi, M. Silva, O. Martins Filho, D. Queiroz

    Haematologica. 2011, 96, 1560-1564

  72. The role of different subsets of T regulatory cells in controlling autoimmunity

    M. Roncarolo, M. Levings

    Current Opinion in Immunology. 2000, 12, 676-683

  73. FOXP3+ regulatory T cells in the human immune system

    S. Sakaguchi, M. Miyara, C. Costantino, D. Hafler

    Nature Reviews Immunology. 2010, 10, 490-500

  74. Regulatory T cell CD4 ‏&CD25‏ expression and chemokine C-X-C ligand 13 level before and after corticosteroid therapy in pediatric ITP patients

    H. Ahmed, E. Fahmy, E. Nagiub Abdelsalam

    Pediatric Hematology Oncology Journal. 2019, 4, 39-43

  75. Mouse Models for Immune‐Mediated Platelet Destruction or Immune Thrombocytopenia (ITP)

    A. Neschadim, D. Branch

    Current Protocols in Immunology. 2016, 113,

  76. Acute Systemic Reaction and Lung Alterations Induced by an Antiplatelet Integrin gpIIb/IIIa Antibody in Mice

    B. Nieswandt, B. Echtenacher, F. Wachs, J. Schröder, J. Gessner, R. Schmidt, G. Grau, D. Männel

    Blood. 1999, 94, 684-693

  77. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbα antibodies

    M. Webster, E. Sayeh, M. Crow, P. Chen, B. Nieswandt, J. Freedman, H. Ni

    Blood. 2006, 108, 943-946

  78. Pharmacokinetic/Pharmacodynamic Modeling of IVIG Effects in a Murine Model of Immune Thrombocytopenia

    R. Deng, J. Balthasar

    Journal of Pharmaceutical Sciences. 2007, 96, 1625-1637

  79. A murine model of severe immune thrombocytopenia is induced by antibody- and CD8+ T cell–mediated responses that are differentially sensitive to therapy

    L. Chow, R. Aslam, E. Speck, M. Kim, N. Cridland, M. Webster, P. Chen, K. Sahib, H. Ni, A. Lazarus, M. Garvey, J. Freedman, J. Semple

    Blood. 2010, 115, 1247-1253

  80. CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia

    L. Ma, E. Simpson, J. Li, M. Xuan, M. Xu, L. Baker, Y. Shi, I. Yougbaré, X. Wang, G. Zhu, P. Chen, G. Prud’homme, A. Lazarus, J. Freedman, H. Ni

    Blood. 2015, 126, 247-256

  81. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25)

    Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M

    J Immunol . 1995, 155, 1151

  82. Critical role of CD4+CD25+ regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia

    T. Nishimoto, T. Satoh, T. Takeuchi, Y. Ikeda, M. Kuwana

    Experimental Hematology. 2012, 40, 279-289

  83. Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia

    T. Nishimoto, M. Numajiri, H. Nakazaki, Y. Okazaki, M. Kuwana

    International Journal of Hematology. 2014, 100, 341-344

  84. Of Mice and Not Men: Differences between Mouse and Human Immunology

    J. Mestas, C. Hughes

    The Journal of Immunology. 2004, 172, 2731-2738

  85. Mathematical Techniques for Understanding Platelet Regulation and the Development of New Pharmacological Approaches

    Dunster JL, Panteleev MA, Gibbins JM, Sveshnikova AN

    Platelets and Megakaryocytes. 2018, 1812, 255-79

  86. Systems approaches meet biology and physiology: why do we need yet another journal?

    M. Panteleev

    System Biology and Physiology Reports. 2021, 1, 1-2

  87. Modeling and Simulation Support Eltrombopag Dosing in Pediatric Patients With Immune Thrombocytopenia

    M. Wire, X. Li, J. Zhang, W. Sallas, V. Aslanis, T. Ouatas

    Clinical Pharmacology & Therapeutics. 2018, 104, 1199-1207

  88. Heterogeneity of Integrin αIIbβ3 Function in Pediatric Immune Thrombocytopenia Revealed by Continuous Flow Cytometry Analysis

    A. Martyanov, D. Morozova, M. Sorokina, A. Filkova, D. Fedorova, S. Uzueva, E. Suntsova, G. Novichkova, P. Zharkov, M. Panteleev, A. Sveshnikova

    International Journal of Molecular Sciences. 2020, 21, 3035

  89. A strong correlation exists between platelet consumption and platelet hyperactivation in COVID-19 patients. Pilot study of the patient cohort from CCH RAS Hospital (Troitsk).

    M. Stepanyan, A. Martyanov, O. An, A. Boldova, S. Roumiantsev, A. Rumyantsev, M. Panteleev, F. Ataullakhanov, A. Sveshnikova

    Systems Biology and Physiology Reports. 2021, 1, 1-10